v3.26.1
Debt
 6 Months Ended
Jun. 30, 2026
Debt Disclosure [Abstract]  
Debt Debt
The Company’s outstanding debt is shown in the following table (dollars in thousands):
Maturity
Dates		Interest
Rates		June 30,December 31,
20262025
Term loans secured by all assets12/2026 - 4/2031
4.00 - 9.00%
$18,264 $19,578 
Term loans secured by property and equipment09/2026 - 01/2030
3.41 - 7.82%
4,816 5,813 
Line of credit secured by all assets09/20266.75%98 740 
Term loans of Real Estate VIEs05/2028 - 03/2037
3.50 - 3.59%
9,921 10,563 
Seller note09/20358.00%5,800 5,800 
Deferred payment09/203510.00%1,000 1,000 
Total39,899 43,494 
Less: unamortized issuance costs and discount200 244 
Less: short-term lines of credit98 740 
Less: current portion of long-term debt8,496 13,336 
Total long-term debt$31,105 $29,174 
Term loans and lines of credit. We have entered into private debt arrangements with banking institutions for the purchase of equipment and to provide working capital and liquidity through cash and lines of credit. Unless otherwise delineated above, these debt arrangements are obligations of Nutex and/or its wholly-owned subsidiaries. Consolidated real estate entities have entered into private debt arrangements with banking institutions for purposes of purchasing land, constructing new emergency room facilities and building out leasehold improvements which are leased to our hospital entities. Nutex is a guarantor or, in limited cases, a co-borrower on the debt arrangements of the Real Estate VIEs for the periods shown.
Certain outstanding debt arrangements require minimum debt service coverage ratios and other financial covenants. At June 30, 2026, we were in compliance with these debt arrangements; we had remaining availability of $3.4 million under outstanding lines of credit. On June 30, 2026, we were issued an irrevocable standby letter of credit in the amount of $1.7 million to support certain lease obligations. As of June 30, 2026, no amounts had been drawn under the line of credit, and no liability has been recorded for the undrawn amount. Under the terms of the contractual agreement, the Company reclassified $1.7 million from cash and cash equivalents to restricted cash because the funds are held by the bank and required to be maintained under the related arrangement.
There have been no significant changes to the terms of the Company's debt and covenants from those disclosed in Note 8 to the financial statements presented in the 2025 Form 10-K.